English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The multidrug treatment, CDF (cyclophos- phamide (CPA), doxorubicin (DXR), and 5- fluorouracil (5-FU)), is a common chemotherapy protocol for breast cancer. However, the molecular mechanisms underlying its toxicity for breast cancer cells remain unclear. As a laboratory model of breast cancer chemotherapy, the human breast cancer cell line MCF-7 was treated with CDF or the individual CDF reagents. Western blotting analysis revealed that two effector caspases (-6 and -7) were activated following the administration of DXR, 5-FU, or the CDF multi-drug. However, after treatment with CPA alone, caspase-7 was activated, but caspase-6 was not. We next used the RNA arbitrarily primed- PCR differential display (RAP-PCR DD) method, a derivative of the differential display method, to reveal changes in gene expression with the individual or multi-anticancer drug treatment. RAP-PCR DD was performed using arbitrary PCR primers. Indepen- dent cDNA bands representing at least nine mRNA species were amplified after drug treatment. Our results strongly suggested that the administration of different single and multi-anticancer drug treatments induced the expression of several different genes, whose products may be involved in the induction of cancer cell death.

journal of health science

Profiles of Caspase Activation and Gene Expression in Human Breast Cancer Cell Line MCF-7, after Cyclophosphamide, Doxorubicin, 5-Fluorouracil (CDF) Multi-Drug Administration